Skip to content

CapEx at other companies

Biogen logo
BiogenBIIB
$51.2M+38.0%
Edgewise Therapeutics, Inc. logo
Edgewise Therapeutics, Inc.EWTX
$260K+491%
PTC Therapeutics logo
PTC TherapeuticsPTCT
$1.2M-30.6%
Dyne Therapeutics, Inc. logo
Dyne Therapeutics, Inc.DYN
$221K-77.5%
Catalyst Pharmaceutical logo
Catalyst PharmaceuticalCPRX
$27K
Cogent Biosciences, Inc. logo
Cogent Biosciences, Inc.COGT
$449K-17.9%

Other financials

Income statement

See full
Revenue-
Operating income-$102.0M-32.3%
Net income-$105.5M-41.2%
EPS (diluted)-$0.83-23.9%

Balance sheet

See full
Cash & equivalents$430.5M+212%
Total debt$205.7M+226%
Total equity$276.0M-11.6%
Total assets$535.3M+31.3%

Cash flow

See full
Operating cash flow-$82.1M-4.4%
Free cash flow-$82.2M-4.1%

Valuation

See full
Market cap$5.67B+85.5%

Profitability

See full
Operating margin-231.8%
Net margin-236.9%
FCF margin-309.1%

Returns & leverage

See full
Return on equity-138.9%+60.1pp
Debt / equity0.7×+0.5×
Current ratio8.6×-1.6×

Where this comes from

Reported directly by Scholar Rock in its filing.

Tagged under the XBRL concept us-gaap:PaymentsToAcquirePropertyPlantAndEquipment.

The official record: Scholar Rock’s 10-Q, filed May 7, 2026, on SEC EDGAR. View the filing →

Ask your AI about Scholar Rock's capex.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude

Questions, answered.

What is Scholar Rock's capex?
Scholar Rock (SRRK) reported capex of $68K in Q1 2026.
How has Scholar Rock's capex changed year-over-year?
Scholar Rock's capex decreased by 74.9% year-over-year, from $271K to $68K.
What is the long-term trend for Scholar Rock's capex?
Over 3 years (2021 to 2025), Scholar Rock's capex has grown at a -51.4% compound annual growth rate (CAGR), from $5.25M to $602K.
What does capex mean?
Cash spent on property, plant, and equipment — the primary measure of investment in productive capacity and infrastructure.